Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / People / Terese Hammond
Person

Terese Hammond

Tracked across 1 events · 6 articles · First seen Apr 01, 2026 · Last active May 28, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 60
Tech
MiNK Therapeutics Doses First Patient
MiNK Therapeutics announced the dosing of the first patient in its randomized Phase 2 clinical trial (C-1300-02) evaluating agenT-797 for severe acute lung injury and critical illness. The trial, conducted in collaboration with First Lviv…
Impact: As Head of R&D at MiNK Therapeutics, Terese Hammond provided insights into the trial's design and its potential to address immune dysfunction in critically ill patients.
May 28, 2026 · 6 articles
NEWSDESK
Track Terese Hammond live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.